Who are KCI Medical?
KCI are a global advanced wound care company that leverages the strengths of Kinetic Concepts, Inc. and Systagenix Wound Management, Limited. Headquartered in San Antonio, Texas, with a team of nearly 5,000 people around the world. KCI™ products are designed to address Advanced Wound Therapy needs with best-in-class solutions that deliver superior clinical outcomes for patients.
How has KCI Medical improved patient safety and care across the health sector?
Direct and indirect costs related to wound care contribute to the overall healthcare expenditure and are anticipated to increase with the aging population. Moreover, wound treatment costs can increase when wound complications, such as infection, oedema, and poor perfusion, develop, causing further delays in wound healing. It is critical to balance the benefits of lower costs of wound healing dressings against those of advanced technologies. The use of advanced technologies, such as negative pressure wound therapy and instillation therapy, may facilitate earlier wound closure and be more cost effective compared to lower cost products that take longer, or fail, to heal the wound.[1]
What has been your greatest achievement to date? And were there any measurable outcomes that accompanied this achievement?
For more than 20 years KCI Medical has supported clinicians to deliver healing outcomes with negative pressure wound therapy they can trust. This body of evidence includes over 72 randomised clinical trials and over 1,200 peer reviewed articles. KCI Medical continue to innovative in this field and will present the latest outcomes in severe pressure ulcers using a novel therapy available to the NHS.
How many organisations currently utilise the systems/solution across the UK?
KCI support 80% of NHS Trusts across England with their negative pressure wound therapy devices. More trusts each year are using the latest novel technology.
What would you like to tell the attendees in advance of the conference, and when considering a partnership with KCI Medical?
Luc Teot MD, PhD, Assistant Professor of Plastic Reconstructive Surgery, Montpellier University Hospital will explain how the treatment of patients with severe pressure ulcers can be improved using negative pressure wound therapy with instillation. New pressure ulcers are estimated to occur in 4–10% of patients admitted to hospitals in the UK; the precise rate depends on case mix, affecting 700,000 people each year with around 186,617 patients developing a pressure ulcer in hospital (NICE Pressure Ulcer Quality Standard 2015). Mr Teot will present the latest clinical evidence and explain why these complex pressure ulcers present additional challenges and costs of care.
The KCI staff will be on the stand to explain the therapy to visitors.
(1) Baharestani MM, Driver VR, De Leon JM et al. Optimizing clinical and cost effectiveness with early intervention of V.A.C. therapy. Ostomy Wound Manage 2008 November 1;54 (11 Suppl) :1-15.
Find out more at www.kci-medical.ie
Comments